Skip to content
AnalystLens

Charles River Laboratories International Annual Report, Year Ended Dec 27, 2025

Filing Date
Filed February 18, 2026
Period End
December 27, 2025
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Jun ’16Jun ’16
  2. Deal closed8-K · May ’19May ’19
  3. Leadership change8-K · May ’21May ’21
  4. Leadership change8-K · May ’25May ’25

Summary

Summary of the 10-K filed February 18, 2026. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. (CRL) reported fiscal 2025 total revenue of $4.02 billiona, down 0.9% from $4.05 billion in fiscal 2024, as lower DSA volumes outweighed higher RMS revenue.

The company swung to a net loss available to common shareholders of $144.3 millionb (basic and diluted loss per share of $2.91), compared with net income of $10.3 million in 2024. The decline was driven by $210.97 million of intangible asset impairments, a $165.0 million goodwill impairment in Biologics Solutions, and a $102.0 million intangible impairment within RMS's Cell Solutions group. Operating income fell to $25.2 million (0.6% margin) from $227.3 million, and the effective tax rate was (42.9)%.

Segment results show DSA revenue of $2.40 billionc (59.8% of total) with operating income of $424.6 million, RMS revenue of $846.1 million with operating income of $44.6 million, and Manufacturing revenue of $766.4 million with an operating loss of $184.3 million. Management described early signs of demand improvement, particularly from large biopharma clients in DSA, and expects approximately $300 million in cumulative annualized cost savings by the end of 2026. Operating cash flow was $737.6 million, and total debt and finance leases were $2.1 billion at year-end.

The company also disclosed that it acquired certain assets of K.F. (Cambodia) Ltd. in January 2026 for $510.0 milliond, plans to acquire the remaining 79% of PathoQuest SAS for approximately $60 million, and expects to divest non-core assets representing about 7% of 2025 revenue. Leadership is changing: James C.

Foster will step down as CEO and Chair effective May 5, 2026, and Birgit Girshick has been appointed as his successor. The company faces ongoing litigation, including a putative securities class action that was partially reinstated on appeal in August 2025, and two stayed derivative lawsuits.

Management says it cannot estimate the potential exposure from these matters. The SEC closed its investigation in November 2025 without recommending enforcement, and the DOJ closed its related grand jury and civil investigations in August 2025.

Key Highlights

  1. Fiscal 2025 revenue was $4.02 billion, down 0.9% from $4.05 billion, with DSA revenue down 2.0% and RMS revenue up 2.0%.
  2. Net loss available to common shareholders was $144.3 million (EPS of $(2.91)), versus net income of $10.3 million in fiscal 2024, driven by impairments totaling more than $480 million across intangible assets and goodwill.
  3. Operating income fell to $25.2 million (0.6% margin) from $227.3 million (5.6% margin) in fiscal 2024.
  4. Manufacturing posted an operating loss of $184.3 million, including a $165.0 million goodwill impairment in Biologics Solutions and a $109.0 million intangible impairment in the CDMO Gene Therapy asset group.
  5. Operating cash flow was $737.6 million, and the company repurchased $350.0 million of stock under its prior program; a new $1.0 billion authorization was approved in October 2025 with $1.0 billion remaining at year-end.
  6. Management expects approximately $300 million in cumulative annualized cost savings by the end of 2026, with $175 million benefiting fiscal 2025, and plans to close or consolidate about 12 additional sites over the next two years.
  7. Leadership transition: CEO James C. Foster retires May 5, 2026, and COO Birgit Girshick will become CEO.

Financial Statements

FY2025 against FY2024

Line itemFY2025FY2024Change
Revenue$4.02B$4.05B−0.9%
SG&A Expenses$743.07M$751.00M−1.1%
Operating Income$25.16M$227.35M−88.9%
Net Income-$144.34M$10.30M−1501.7%
EPS (Basic)$-2.91$0.20−1555.0%
EPS (Diluted)$-2.91$0.20−1555.0%
Shares Outstanding (Basic)49.56M51.38M−3.5%
Shares Outstanding (Diluted)49.56M51.63M−4.0%

Frequently Asked Questions

  1. Why did Charles River report a net loss in fiscal 2025?

    The net loss was driven primarily by non-cash charges: a $210.97 million intangible asset impairment (including $102.0 million in RMS Cell Solutions and $109.0 million in the Manufacturing CDMO Gene Therapy group), a $165.0 million goodwill impairment in Biologics Solutions, and higher amortization of intangible assets of $179.1 million. Lower DSA volumes and restructuring charges of $99.8 million also reduced operating income.

  2. How did the company's segments perform?

    DSA revenue was $2.40 billion with operating income of $424.6 million (17.7% margin). RMS revenue rose 2.0% to $846.1 million, but operating income fell to $44.6 million because of the Cell Solutions impairment. Manufacturing revenue was $766.4 million, but it posted an operating loss of $184.3 million due to impairments and a goodwill charge.

  3. What acquisitions and divestitures did the company announce?

    In January 2026, the company acquired certain assets of K.F. (Cambodia) Ltd. for $510.0 million, with $335.0 million paid upfront and $175.0 million deferred. It also agreed to acquire the remaining 79% equity interest in PathoQuest SAS for €51.6 million (about $60 million), expected to close in the first quarter of 2026. The company expects to sell certain non-core businesses representing approximately 7% of its 2025 revenue.

  4. What is the status of the legal matters involving non-human primate sourcing?

    The SEC's Division of Enforcement notified the company on November 14, 2025, that it does not intend to recommend enforcement, and the DOJ closed its grand jury and parallel civil investigations in August 2025. A putative securities class action was partially reinstated by the First Circuit on August 15, 2025, and remains pending in the District of Massachusetts. Two derivative lawsuits in Delaware are stayed. The company believes these claims are without merit but cannot estimate its potential exposure.